Go Ad-Free
    My Alerts
    Moneycontrol
    Moneycontrol PRO
    HomeNewsWockhardt

    Jump to
    • Expect to maintain EBIDTA margin ahead: Wockhardt

      Expect to maintain EBIDTA margin ahead: Wockhardt

      Habil Khorakiwala, chairman of Wockhardt says, the company‘s EBITDA margin is increasing QoQ for nine consecutive quarters. "We believe that we should be able to maintain the margin, if not improve upon it," he adds.

    • Wockhardt sees healthy 30% margins in FY12

      Wockhardt sees healthy 30% margins in FY12

      In an interview to CNBC-TV18, Habil Khorakiwala, chariman of the Wockhardt Group said the EBITDA growth for FY12 is likely to be at 72%, while the margins are seen at 30%.

    • NPPA's move to positively impact insulin sales: Biocon

      NPPA's move to positively impact insulin sales: Biocon

      Speaking to CNBC-TV18, Kiran Mazumdar Shaw, chairman and ,managing director of Biocon said," I am glad that NPPA has given us this price increase. It still puts us at a discount to other multinationals and importers of insulin but at least one step at a time."

    Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347